RT Journal Article
T1 Treatment for hemophilia: recombinant versus plasma-derived coagulationfactors – controversy and debateforever? An ethical medical challenge?
A1 Liras, Antonio
A1 García-Tenchard, Rebecca
AB With the eradication of infection by HIV and hepatitis C virus that were common just a few years ago, the most concerning adverse effect resulting from the use of both recombinant and plasma-derived products is the appearance of antibodies (inhibitors) to perfused exogenous factors.”
PB Informa Healthcare
SN 1747-4086,  1747-4094 (ESSN)
YR 2013
FD 2013-10
LK https://hdl.handle.net/20.500.14352/34703
UL https://hdl.handle.net/20.500.14352/34703
LA eng
NO Victoria Eugenia Royal Foundation of Hemophilia
DS Docta Complutense
RD 11 abr 2025